BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

CISBIO Launches HTRF(R) Terbium Platform for GPCR Screening at SBS


4/7/2008 11:58:20 AM

Bagnols-sur-Cèze, France and St. Louis, MO, U.S.A. – April 7, 2008 – Cisbio, a global developer of HTRF® (Homogeneous Time-Resolved Fluorescence) technology and services used in assay development and drug screening, today announced the launch of its HTRF Terbium platform for GPCR screening, with the introduction of IP-One Tb and cAMP Tb. These assays mark the first products in Cisbio’s second-generation HTRF technology pipeline to incorporate the Lumi4™-Tb cryptate for enhanced screening performance.

Lumi4-Tb, a Terbium cryptate developed by Lumiphore, Inc. and licensed exclusively to Cisbio for the drug discovery field of use, is the newest member of Cisbio’s family of cryptates on which HTRF chemistry is based. HTRF is Cisbio’s highly sensitive, robust technology for the detection of molecular interactions in vitro and is widely used for primary and secondary screening phases of drug development. Lumi4-Tb’s structure, a lanthanide tightly embedded in a surrounding macrocycle, remains very much in line with that of previous HTRF cryptates and shows superior stability compared to other Terbium complexes. It therefore allows for enhanced assay performance in terms of sensitivity, assay window, and robustness, without compromising the features and benefits that HTRF brings to assays: a “mix and measure” non-radioactive format, miniaturizable to uHTS formats, showing excellent robustness and a low compound interference rate.

Cisbio has long been a leader in the development of tools for researchers in G-Protein Coupled Receptors (GPCRs), one of the most important target classes investigated within drug discovery. Launched in 2005, IP-One was the first cell-based high throughput system to easily detect inositol(1)phosphate (IP1), one of the major products of the phosphatidyl

inositol cascade and which tightly correlates with Gq-coupled activity. Reformatted with Lumi4-Tb instead of a Europium cryptate, IP-One Tb offers increased sensitivity and an enhanced signal-to-noise ratio, and can be easily adopted by current users as it involves the same protocol as before. Cisbio’s cAMP assays, which run on the same industry-standard hardware and follow the same methodology and procedure as IP-One, have also been extended to include cAMP Tb, thereby creating a Terbium technological platform for investigators to assess all GPCR targets that can be used with any existing HTRF-compatible instrument.

“As a pioneer in TR-FRET technologies, Cisbio recognized the need to create a new generation of functional tools to meet a new generation of industry needs,” said François Degorce, head of HTRF Marketing and Business Development at Cisbio. “We selected the best possible chemistry to complement our robust Europium cryptates, and this new Terbium cryptate will enable us to provide GPCR researchers with enhanced, easy-to-use tools that further improve assay implementation.” The incorporation of Lumi4-Tb into IP-One Tb and cAMP Tb is the first step towards integrating this new chemistry into Cisbio’s broad range of assays. Lumi4-Tb will also be available on request to Cisbio’s customers for custom labelling and assay development services.

About Cisbio Bioassays Cisbio Bioassays is a global developer of products and technologies used in nuclear medicine, in vitro diagnostics and assay development for drug screening procedures. The company pioneered the field of homogenous fluorescence methodologies via its proprietary technology, HTRF®, a highly sensitive, robust technology for the detection of molecular interactions and widely used by the pharmaceutical industry for the high throughput screening stage of drug development. In addition, Cisbio Bioassays produces a selection of biological reagents and methods used by pharmaceutical and biotechnology companies, as well as contract research organizations (CROs). Headquartered in Saclay, France, Cisbio Bioassays is owned by the Belgium consortium RadioPharma Partners, has facilities in Bagnols-sur-Cèze, France and Bedford, MA, U.S.A. and markets its products worldwide through a network of distributors. For more information about Cisbio and HTRF, log onto www.cisbio.com and www.htrf.com. HTRF® is a registered trademark of Cisbio Bioassays. Lumi4™-Tb is a trademark of Lumiphore, Inc.

Read at BioSpace.com

CISBIO
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES